Showing results (151-160 of 163) with videos related to
Sort By:
Pageof 17
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.Medrxiv : the Preprint Server for Health Sciences|August 21, 2020
Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 seraKasopefoluwa Y Oguntuyo, Christian S Stevens, Chuan-Tien Hung, et al.Mbio|February 17, 2021
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 SeraKasopefoluwa Y Oguntuyo, Christian S Stevens, Chuan Tien Hung, et al.Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.Cell Host & Microbe|September 11, 2015
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesM Anthony Moody, Feng Gao, Thaddeus C Gurley, et al.The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.Pageof 17